Astragaloside IV alleviates heart failure by modulating Nrf-2

Astragaloside IV alleviates heart failure by modulating Nrf-2

Bibliographic Details
Main Authors:	Wenxiao Feng, Jie Yang, Yan Li, Haiyan Sun, Juan Zhang, Yitao Xue, Ningning Wang, Jing Ni
Format:	Article
Language:	English
Published:	Wolters Kluwer 2022-05-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000001828

Similar Items

Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway
by: Yan-Bo Sui, et al.
Published: (2019-01-01)

Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation
by: Zhiwei Dong, et al.
Published: (2017-06-01)

Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway
by: Ping Gao, et al.
Published: (2021-01-01)

Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice
by: Ling Zhou, et al.
Published: (2020-10-01)

Astragaloside IV attenuates lipopolysaccharide induced liver injury by modulating Nrf2-mediated oxidative stress and NLRP3-mediated inflammation
by: Yuxia Sun, et al.
Published: (2023-04-01)

Astragaloside-IV Alleviates Heat-Induced Inflammation by Inhibiting Endoplasmic Reticulum Stress and Autophagy
by: Zhiwei Dong, et al.
Published: (2017-06-01)

Astragaloside IV Alleviates Infarction Induced Cardiomyocyte Injury by Improving Mitochondrial Morphology and Function
by: Wen Zhang, et al.
Published: (2022-02-01)

Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats
by: Wei Liu, et al.
Published: (2019-01-01)

Astragaloside IV, as a potential anticancer agent
by: Dongqin Xia, et al.
Published: (2023-02-01)

Astragaloside IV alleviates 1-deoxysphinganine-induced mitochondrial dysfunction during the progression of chronic kidney disease through p62-Nrf2 antioxidant pathway
by: Ting Gui, et al.
Published: (2023-03-01)

Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network.
by: Xinhui Liu, et al.
Published: (2017-01-01)

Astragaloside IV Alleviates Brain Injury Induced by Hypoxia via the Calpain-1 Signaling Pathway
by: Yan Meng, et al.
Published: (2022-01-01)

Astragaloside IV alleviates lipopolysaccharide‐induced preeclampsia‐like phenotypes via suppressing the inflammatory responses
by: Dilihuma Tuerxun, et al.
Published: (2021-03-01)

Astragaloside IV attenuates ferroptosis after subarachnoid hemorrhage via Nrf2/HO-1 signaling pathway
by: Zhuanghua Liu, et al.
Published: (2022-08-01)

Astragaloside IV alleviates lung inflammation in Klebsiella pneumonia rats by suppressing TGF-β1/Smad pathway
by: Lei Li, et al.
Published: (2023-07-01)

Effect of Astragaloside IV on improving cardiac function in rats with heart failure: a preclinical systematic review and meta-analysis
by: Zhiyuan Zhang, et al.
Published: (2023-10-01)

Pharmacological Effects of Astragaloside IV: A Review
by: Yutong Liang, et al.
Published: (2023-08-01)

Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV
by: Zehui Xu, et al.
Published: (2023-12-01)

Astragaloside IV Regulates cGAS-STING Signaling Pathway to Alleviate Immunosuppression Caused by PRRSV Infection
by: Ke Song, et al.
Published: (2023-07-01)

Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling
by: Lianlian Tian, et al.
Published: (2021-09-01)

The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease
by: Yiwei Gao, et al.
Published: (2023-07-01)

Astragaloside alleviates alcoholic fatty liver disease by suppressing oxidative stress
by: Zhi‐Bin Jiang, et al.
Published: (2021-08-01)

Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling
by: Fei Xu, et al.
Published: (2018-08-01)

Research progress on the mechanism of astragaloside IV in the treatment of asthma
by: Fanyi Yuan, et al.
Published: (2023-11-01)

Research progress of astragaloside IV in the treatment of atopic diseases
by: Shencun Yu, et al.
Published: (2022-12-01)

Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
by: Tan YQ, et al.
Published: (2020-09-01)

Anti-Fibrotic Effects of Astragaloside IV in Systemic Sclerosis
by: Qing Qi, et al.
Published: (2014-11-01)

Correction: Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling
by: Fei Xu, et al.
Published: (2023-03-01)

Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456
by: Jingjing Wan, et al.
Published: (2023-10-01)

Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII
by: Wanting Qin, et al.
Published: (2024-02-01)

Influence of astragaloside IV on pharmacokinetics of triptolide in rats and its potential mechanism
by: Jian Gao, et al.
Published: (2020-01-01)

Astragaloside IV inhibits experimental autoimmune encephalomyelitis by modulating the polarization of both microglia/macrophages and astrocytes
by: Jingwen Yu, et al.
Published: (2023-07-01)

The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
by: Haoran Jing, et al.
Published: (2021-11-01)

Astragaloside IV-enhanced anti-hepatocarcinoma immunity of dendritic cells
by: Hongxing Guo, et al.
Published: (2022-05-01)

Review on the protective mechanism of astragaloside IV against cardiovascular diseases
by: Chunkun Yang, et al.
Published: (2023-05-01)

Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases
by: Tan J, et al.
Published: (2023-07-01)

Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
by: Sen Sun, et al.
Published: (2022-12-01)

The Effect of Astragaloside IV on Isoproterenol-Induced Myocardial Infarction in Rats
by: Fatemeh Fathizad, et al.
Published: (2019-06-01)

Astragaloside IV inhibits astrocyte senescence: implication in Parkinson’s disease
by: Mei-Ling Xia, et al.
Published: (2020-04-01)

Effects of total astragalosides on cardiomyocyte apoptosis and mitochondrial membrane potential in rats with heart failure
by: YOU Xu, ZHU Xiao-fang, HU Yun-peng, GONG Yang, ZHAO Lei
Published: (2020-09-01)